Antengene (HKSE:06996) Additional Paid-In Capital : HK$6,821.85 Mil(As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Antengene Additional Paid-In Capital?

Antengene's quarterly additional paid-in capital increased from Jun. 2023 (HK$6,919.78 Mil) to Dec. 2023 (HK$6,931.07 Mil) but then stayed the same from Dec. 2023 (HK$6,931.07 Mil) to Jun. 2024 (HK$6,821.85 Mil).

Antengene's annual additional paid-in capital declined from Dec. 2021 (HK$7,783.00 Mil) to Dec. 2022 (HK$7,064.87 Mil) and declined from Dec. 2022 (HK$7,064.87 Mil) to Dec. 2023 (HK$6,931.07 Mil).

Antengene Additional Paid-In Capital Historical Data

The historical data trend for Antengene's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antengene Additional Paid-In Capital Chart

Antengene Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

7,566.99

7,783.00

7,064.87

6,931.07

Antengene Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Additional Paid-In Capital	Get a 7-Day Free Trial								7,064.87	6,919.78	6,931.07	6,821.85	-

Antengene Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Antengene Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Antengene's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Antengene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antengene Corp Ltd (HKSE:06996) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

1065 West Zhongshan Road, Suites 1206-1209, Block B, Zhongshan SOHO Plaza, Changning District, Shanghai, CHN

Website

https://www.antengene.com

Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically it operates in Chinese Mainland, Hong Kong, Macao and Taiwan and Overseas.

Executives

Xyxy Holdings Ltd.	2201 Interest of corporation controlled by you
Boyu Group, Llc	2201 Interest of corporation controlled by you
Boyu Capital Group Holdings Ltd	2201 Interest of corporation controlled by you
Tong Xiaomeng	2201 Interest of corporation controlled by you
Jay Mei 2025 Grat	2201 Interest of corporation controlled by you
Mei Jay	2201 Interest of corporation controlled by you
Jay Mei 2023 Grat	2201 Interest of corporation controlled by you
Fountainvest China Capital Partners Gp3 Ltd.	2201 Interest of corporation controlled by you
Qiming Corporate Gp V, Ltd.
The Core Trust Company Limited	2301 Trustee
Tct (bvi) Limited	2501 Other
Fountainvest China Capital Partners Fund Iii, L.p.	2201 Interest of corporation controlled by you
Begonia Investment Ltd.	2101 Beneficial owner
Fmr Llc	2201 Interest of corporation controlled by you
Fidelity Investment Trust	2101 Beneficial owner

Antengene Headlines

No Headlines